Nuevas posibilidades terapéuticas en melanoma metastásico
Barra lateral del artículo
Contenido principal del artículo
Resumen
El melanoma ha experimentado un aumento constante en su tasa de incidencia en las últimas cinco décadas a nivel mundial. El pronóstico del paciente con melanoma se relaciona con el estadio de la enfermedad al momento del diagnóstico, con una sobrevida global media de 6,2 meses en pacientes con melanoma metastásico. El avance en las investigaciones sobre la biología y el comportamiento tumoral permitió el desarrollo de nuevas terapias con distintos mecanismos de acción y mayor eficacia. En esta revisión se abordan las terapias biológicas en melanoma metastásico, su mecanismo de acción y principales resultados en ensayos clínicos
Downloads
Detalles del artículo
Sección
Esta obra está bajo una licencia internacional Creative Commons Atribución-NoComercial-CompartirIgual 4.0.
Cómo citar
Referencias
Nikolaou V, Stratigos AJ. Emerging trends in the epidemiology of melanoma. Br J Dermatol; 2014, 170 (1):11-9. DOI: https://doi.org/10.1111/bjd.12492
Garbe C, Leiter U. Melanoma epidemiology and trends. Clin Dermatol 2009; 27(1): 3-9. DOI: https://doi.org/10.1016/j.clindermatol.2008.09.001
Balch CM, Buzaid AC, Soong SJ, et al. Final version of the American Joint Committee on Cancer staging system for cutaneous Melanoma. J Clin Oncol 2001;19(16):3635-48 DOI: https://doi.org/10.1200/JCO.2001.19.16.3635
Michielin O, Hoeller C. Gaining momentum: New options and opportunities for the treatment of advanced melanoma. Cancer Treat Rev 2015; 41(8): 660-70. DOI: https://doi.org/10.1016/j.ctrv.2015.05.012
Korn EL, Liu PY, Lee SJ, et al. Meta-analysis of phase II cooperative group trials in metastatic stage IV melanoma to determine progression-free and overall survival benchmarks for future phase II trials. J Clin Oncol 2008; 26: 527-34. DOI: https://doi.org/10.1200/JCO.2007.12.7837
Malumbres M, Barbacid M. Cell cycle, CDKs and cancer: a changing paradigm. Nat Rev Cancer 2009; 9(3):153-66. DOI: https://doi.org/10.1038/nrc2602
Davies H, Bignell GR, Cox C, et al. Mutations of the BRAF gene in human cancer. Nature 2002; 417: 949-54. DOI: https://doi.org/10.1038/nature00766
Long GV, Menzies AM, Nagrial AM, et al. Prognostic and clinicopathologic associations of oncogenic BRAF in metastatic melanoma. J Clin Oncol 2011; 29(10):1239-46. DOI: https://doi.org/10.1200/JCO.2010.32.4327
Chapman PB, Hauschild A, Robert C, et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 2011; 364(26): 2507-16. DOI: https://doi.org/10.1056/NEJMoa1103782
McArthur GA, Chapman PB, Robert C, et al. Safety and efficacy of vemurafenib in BRAF (V600E) and BRAF(V600K) mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study. Lancet Oncol 2014;15(3):323-32. DOI: https://doi.org/10.1016/S1470-2045(14)70012-9
Hauschild A, Grob JJ, Demidov LV, et al. Dabrafenib in BRAF-mutated metastatic melanoma: A multicentre, open-label, phase 3 randomised controlled trial. Lancet 2012;380:358–365. DOI: https://doi.org/10.1016/S0140-6736(12)60868-X
Zhang W. BRAF inhibitors: the current and the future. Curr Opin Pharmacol 2015; 23:68-73. DOI: https://doi.org/10.1016/j.coph.2015.05.015
Karimkhani C, Gonzalez R, Dellavalle RP. A review of novel therapies for melanoma. Am J Clin Dermatol 2014; 15: 323-37. DOI: https://doi.org/10.1007/s40257-014-0083-7
Spagnolo F, Ghiorzo P, Queirolo P. Overcoming resistance to BRAF inhibition in BRAF-mutated metastatic melanoma. Oncotarget 2014; 5:10206-21. DOI: https://doi.org/10.18632/oncotarget.2602
Flaherty KT, Robert C, Hersey P, et al. Improved survival with MEK inhibition in BRAF-mutated melanoma. N Engl J Med 2012; 367:107-14. DOI: https://doi.org/10.1056/NEJMoa1203421
Long GV, Stroyakovskiy D, Gogas H, et al. Combined BRAF and MEK inhibition versus BRAF inhibition Alone in Melanoma. N Engl J Med 2014; 371: 1877-88. DOI: https://doi.org/10.1056/NEJMoa1406037
Larkin JL, Ascierto PA, Dreno B, et al. Combined Vemurafenib and Cobimetinib in BRAF-Mutated Melanoma. N Engl J Med 2014; 371: 1867-76. DOI: https://doi.org/10.1056/NEJMoa1408868
Atkins MB, Lotze MT, Dutcher JP, et al. High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993. J Clin Oncol 1999;17:2105–16. DOI: https://doi.org/10.1200/JCO.1999.17.7.2105
Leach DR, Krummel MF, Allison JP. Enhancement of Antitumor Immunity by CTLA-4 Blockade. Science 1996; 271: 1734-6. DOI: https://doi.org/10.1126/science.271.5256.1734
Ribas A. Releasing the brakes on cancer immunotherapy. N Engl J Med 2015;373:1490-2 DOI: https://doi.org/10.1056/NEJMp1510079
Hodi FS, O ́Day SJ, McDermott DF, et al Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010; 363: 711-23. DOI: https://doi.org/10.1056/NEJMx100063
Robert C, Thomas L, Bondarenko I, et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med 2011; 364: 2517-26. DOI: https://doi.org/10.1056/NEJMoa1104621
Schadendorf D, Hodi FS, Robert C, et al. Pooled Analysis of Long-Term Survival Data From Phase II and Phase III Trials of Ipilimumab in Unresectable or Metastatic Melanoma. J Clin Oncol 2015; 33:1889-94. DOI: https://doi.org/10.1200/JCO.2014.56.2736
Ibrahim RA, Berman DM, De Pril V, et al. Ipilimumab safety profile: summary of findings from completed trials in advanced melanoma. J Clin Oncol 2011; 29 (Suppl): abstr 8583. DOI: https://doi.org/10.1200/jco.2011.29.15_suppl.8583
Hodi FS, Kluger HM, Sznol M, et al. Long-term survival of ipilimumab-naïve patients (pts) with advanced melanoma (MEL) treated with nivolumab (anti-PD-1; BMS-936558, ONO-4538) in a phase 1 trial. Pigment Cell Melanoma Res 2014;27:1169–241. DOI: https://doi.org/10.1200/jco.2014.32.15_suppl.9002
Topalian SL, Sznol M, McDermott DF, et al. Survival, durable tumor remission and long-term safety in patients with advanced melanoma receiving nivolumab. J Clin Oncol 2014; 32: 1020-30. DOI: https://doi.org/10.1200/JCO.2013.53.0105
Ribas A, Hamid O, Daud A, et al. Association of Pembrolizumab With Tumor Response and Survival Among Patients With Advanced Melanoma. JAMA 2016;315:1600-9. DOI: https://doi.org/10.1001/jama.2016.4059
Larkin J, Chiarion-Sileni V, Gonzalez R, et al. Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma. N Engl J Med 2015; 373:23-34. DOI: https://doi.org/10.1056/NEJMoa1504030
Postow MA, Chesney J, Pavlick AC, et al. Nivolumab and ipilimumab in untreated melanoma. N Engl J Med 2015; 372: 2006-17. DOI: https://doi.org/10.1056/NEJMoa1414428